Radiopharm Theranostics Ltd (ASX: RAD) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Radiopharm Theranostics Ltd Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Radiopharm Theranostics Ltd (ASX: RAD)
Latest News
Healthcare Shares
This biotechnology stock just ticked over 100% gains for the month on more good news
Small Cap Shares
2 ASX small-cap shares rocketing 35% to 54% today
Small Cap Shares
'Richest pipeline' in ASX: Expert names 3 small-cap shares to buy
RAD ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Radiopharm Theranostics Ltd
Radiopharm Theranostics Ltd. operates as a pre-clinical and clinical research company. It focuses on the development of radiopharmaceutical products for diagnostic and therapeutic uses in areas of high unmet medical need. The company is headquartered Carlton, Australia.
RAD Share Price History Data provided by Morningstar.
| Date | Close | Change | % Change | Volume | Open | High | Low |
|---|---|---|---|---|---|---|---|
| 20 Nov 2026 | $0.00 | $0.00 | 0.00% | 1,666,666 | $0.00 | $0.00 | $0.00 |
| 19 Nov 2026 | $0.00 | $0.00 | 0.00% | 11,419,577 | $0.00 | $0.00 | $0.00 |
| 18 Nov 2026 | $0.00 | $0.00 | 0.00% | 1,816,011 | $0.00 | $0.00 | $0.00 |
| 17 Nov 2026 | $0.00 | $0.00 | 0.00% | 21,752,520 | $0.00 | $0.00 | $0.00 |
| 16 Nov 2026 | $0.00 | $0.00 | 0.00% | 1,248,716 | $0.00 | $0.00 | $0.00 |
| 13 Nov 2026 | $0.00 | $0.00 | 0.00% | 468,690 | $0.00 | $0.00 | $0.00 |
| 12 Nov 2026 | $0.00 | $0.00 | 0.00% | 623,785 | $0.00 | $0.00 | $0.00 |
| 11 Nov 2026 | $0.00 | $0.00 | 0.00% | 20,184,407 | $0.00 | $0.00 | $0.00 |
| 10 Nov 2026 | $0.00 | $0.00 | 0.00% | 3,796,694 | $0.00 | $0.00 | $0.00 |
| 09 Nov 2026 | $0.00 | $0.00 | 0.00% | 26,084,275 | $0.00 | $0.00 | $0.00 |
| 06 Nov 2026 | $0.00 | $0.00 | 0.00% | 3,493,295 | $0.00 | $0.00 | $0.00 |
| 05 Nov 2026 | $0.00 | $0.00 | 0.00% | 6,115,697 | $0.00 | $0.00 | $0.00 |
| 04 Nov 2026 | $0.00 | $0.00 | 0.00% | 11,288,609 | $0.00 | $0.00 | $0.00 |
| 03 Nov 2026 | $0.00 | $0.00 | 0.00% | 24,480,673 | $0.00 | $0.00 | $0.00 |
| 02 Nov 2026 | $0.01 | $0.00 | 0.00% | 10,433,448 | $0.01 | $0.01 | $0.00 |
| 30 Oct 2026 | $0.01 | $0.00 | 0.00% | 66,268 | $0.00 | $0.01 | $0.00 |
| 29 Oct 2026 | $0.00 | $0.00 | 0.00% | 74,363 | $0.00 | $0.00 | $0.00 |
| 28 Oct 2026 | $0.00 | $0.00 | 0.00% | 123,285 | $0.00 | $0.00 | $0.00 |
| 27 Oct 2026 | $0.00 | $0.00 | 0.00% | 12,107,871 | $0.00 | $0.00 | $0.00 |
| 26 Oct 2026 | $0.01 | $0.00 | 0.00% | 2,918,823 | $0.00 | $0.01 | $0.00 |
| 23 Oct 2026 | $0.00 | $0.00 | 0.00% | 541,452 | $0.00 | $0.00 | $0.00 |
| 22 Oct 2026 | $0.00 | $0.00 | 0.00% | 6,779,489 | $0.00 | $0.00 | $0.00 |
| 21 Oct 2026 | $0.00 | $0.00 | 0.00% | 3,017,597 | $0.00 | $0.00 | $0.00 |
Director Transactions Data provided by Morningstar.
| Date | Director | Type | Amount | Value | Notes |
|---|---|---|---|---|---|
| 09 Nov 2026 | Paul Hopper | Sell | 1,111,111 | $3,333 |
As advised by the company. Sale of Shares
|
| 05 Nov 2026 | Bruce Goodwin | Sell | 1,111,111 | $3,913 |
As advised by the company. Sale of Shares
|
| 05 Nov 2026 | Ian Turner | Sell | 1,111,111 | $3,913 |
As advised by the company. Sale of Shares
|
| 05 Nov 2026 | Riccardo Canevari | Sell | 1,555,556 | $5,494 |
As advised by the company. Sale of Shares
|
| 16 Oct 2026 | Ian Turner | Cancelled | 1,111,111 | $4,444 |
Cancellation of securities.
|
| 16 Oct 2026 | Riccardo Canevari | Cancelled | 1,555,556 | $6,222 |
Cancellation of securities.
|
| 16 Oct 2026 | Bruce Goodwin | Cancelled | 1,111,111 | $4,444 |
Cancellation of securities.
|
| 16 Oct 2026 | Paul Hopper | Cancelled | 1,111,111 | $4,444 |
Cancellation of securities.
|
| 30 Sep 2026 | Riccardo Canevari | Expiry | 24,000,000 | $144,000 |
Options expired.
|
| 17 Sep 2026 | Ian Turner | Issued | 1,222,222 | $10,999 |
Participation in share purchase plan. AUD 0.009 per Share
|
| 17 Sep 2026 | Riccardo Canevari | Issued | 3,888,889 | $35,000 |
Participation in share purchase plan.
|
| 17 Sep 2026 | Ian Turner | Issued | 1,555,556 | $14,000 |
Participation in share purchase plan. AUD 0.009 per Share
|
| 17 Sep 2026 | Riccardo Canevari | Issued | 3,888,889 | $27,222 |
Participation in share purchase plan.
|
| 17 Sep 2026 | Ian Turner | Issued | 2,777,778 | $19,444 |
Participation in share purchase plan.
|
| 17 Sep 2026 | Bruce Goodwin | Issued | 2,777,778 | $25,000 |
Participation in share purchase plan.
|
| 17 Sep 2026 | Bruce Goodwin | Issued | 2,777,778 | $19,444 |
Participation in share purchase plan.
|
| 17 Sep 2026 | Paul Hopper | Issued | 2,777,778 | $19,444 |
Participation in share purchase plan.
|
| 17 Sep 2026 | Paul Hopper | Issued | 2,777,778 | $25,000 |
Participation in share purchase plan.
|
| 24 Aug 2026 | Riccardo Canevari | Expiry | 1,875,000 | $20,625 |
Options expired.
|
| 24 Aug 2026 | Hester Larkin | Expiry | 275,000 | $3,025 |
Options expired.
|
| 24 Aug 2026 | Paul Hopper | Expiry | 27,500,000 | $302,500 |
Options expired.
|
| 24 Aug 2026 | Ian Turner | Expiry | 1,875,000 | $20,625 |
Options expired.
|
| 25 Mar 2026 | Ian Turner | Buy | 730,000 | $13,870 |
On-market trade.
|
| 12 Dec 2025 | Paul Hopper | Issued | 18,142,000 | $344,698 |
Issue of options. Non-cash
|
| 12 Dec 2025 | Ian Turner | Issued | 6,814,000 | $129,466 |
Issue of options. Non cash
|
| 12 Dec 2025 | Riccardo Canevari | Issued | 74,338,000 | $1,412,422 |
Issue of options. Non-cash options
|
| 25 Nov 2025 | Ian Turner | Expiry | 1,900,002 | $39,900 |
Options expired.
|
Directors & Management Data provided by Morningstar.
| Name | Title | Start Date | Profile |
|---|---|---|---|
| Mr Paul Alex Hopper | Executive ChairmanFounderExecutive Director | Feb 2021 |
Mr Hopper has over 20 years of experience in the management and funding of biotechnology and healthcare companies in Australia and the United States. Mr Hopper founded and has been involved with a number of biotechnology and healthcare companies. His experience includes corporate management, business development, company funding, and commercial activities within the healthcare and life sciences sectors. Mr Hopper has also been involved in corporate transactions and the development of biotechnology businesses across a range of markets.
|
| Mr Ian Turner | Non-Executive Director | Apr 2021 |
Mr Turner has experience in the nuclear medicine, radiopharmaceutical and radiochemical sectors. Mr Turner held management roles within radiopharmaceutical manufacturing and distribution businesses, including organisations involved in radioisotope production and nuclear medicine services. His experience includes business management, manufacturing operations, supply chain activities and commercial development within the radiopharmaceutical industry. Since 2013, Mr Turner has provided advisory services relating to acquisition opportunities and business development activities in the fields of nuclear medicine, radiochemicals and radiopharmaceuticals.
|
| Mr Riccardo Canevari | Chief Executive OfficerManaging Director | Sep 2021 |
Mr Canevari has experience in the pharmaceutical, radiopharmaceutical and nuclear medicine sectors. He worked with Advanced Accelerator Applications, where his responsibilities included commercial strategy and oversight of country operations across North America, Europe and Asia. Prior to this, Mr Canevari held roles within Novartis Oncology and Novartis Pharma. His experience includes commercial management, business development, product strategy and operational management across international markets. He has also held management roles with Ethicon and Johnson & Johnson.
|
| Ms Hester Larkin | Non-Executive Director | Feb 2022 |
Ms Larkin has experience in the diagnostic imaging, pharmaceutical and biotechnology sectors. Since 2008, she has provided consulting services across projects ranging from pre-clinical and clinical development through to regulatory submissions, medical advisory activities, manufacturing arrangements and commercial partnerships. Prior to this, Ms Larkin held management roles with Bristol-Myers Squibb and DuPont Pharmaceuticals. Her experience includes business development, commercial management, marketing and operational activities across European and international markets.
|
| Mr Noel Donnelly | Non-Executive Director | Oct 2024 |
Mr Donnelly has experience in finance, research and development, strategy, portfolio management, financial planning and analysis, project management, business partnering, valuation and decision-support analysis. Mr Donnelly has held finance and operational roles within the biotechnology and pharmaceutical sectors. His experience includes financial management, research and development operations, portfolio management, project evaluation and cross-functional team leadership. Prior to joining the Company, Mr Donnelly held roles with PEPGEN, EIP Pharma and Takeda/Shire, where he was involved in finance, business operations and research and development activities.
|
| Mr Bruce Goodwin | Non-Executive Director | Nov 2025 |
Mr Goodwin has experience across the health sector in Australia and the United States. Mr Goodwin has worked in sales and marketing, finance, business development and operational management roles. His experience includes strategic planning, business development, organisational management and advisory services within the biopharmaceutical, medical device and healthcare sectors. Prior to this, Mr Goodwin held leadership roles within the healthcare industry and was involved in the management of operations across multiple countries.
|
| Mr Nathan Kim -liung Jong | Joint Company Secretary |
-
|
|
| Ms Amritha Sushil | Joint Company Secretary | May 2026 |
-
|
| Aaron Laurita | CFO |
-
|
|
| Dimitris Voliotis | Chief Medical Officer |
-
|
|
| Nathan Kim -liung Jong | Joint Company Secretary |
-
|
|
| Amritha Sushil | Joint Company Secretary |
-
|
Top Shareholders Data provided by Morningstar.
| Name | Shares | Capital |
|---|---|---|
| BNP Paribas Nominees Pty Ltd | 1,487,980,800 | 34.30% |
| Lantheus Omega LLC Wholly Owned Subsidiary Of Lantheus Holdings Inc | 537,958,513 | 12.40% |
| HSBC Custody Nominees | 203,065,059 | 4.68% |
| UBS Nominees Pty Ltd | 153,352,695 | 3.54% |
| BNP Paribas Noms Pty Ltd | 138,052,666 | 3.18% |
| J P Morgan Nominees Australia Pty Limited | 124,195,099 | 2.86% |
| Adman Lanes Pty Ltd | 121,097,581 | 2.79% |
| Morgan Stanley Australia Securities (Nominee) Pty Limited | 116,947,117 | 2.70% |
| Citicorp Nominees Pty Limited | 100,285,151 | 2.31% |
| NM Investment Limited | 94,858,929 | 2.19% |
| Kilinwata Investments Pty Ltd | 93,571,428 | 2.16% |
| HSBC Custody Nominees (Australia) Limited (I) | 68,861,998 | 1.59% |
| Dulyne Pty Ltd | 52,500,000 | 1.21% |
| Paul Hopper | 52,400,000 | 1.21% |
| HSBC Custody Nominees (Australia) Limited (II) | 30,200,971 | 0.70% |
| Palm Beach Nominees Pty Limited | 29,296,829 | 0.68% |
| Mr Heng Chen | 24,919,395 | 0.57% |
| Scarlett Hopper | 23,857,142 | 0.55% |
| BNP Paribas Nominees Pty Ltd (i) | 20,099,840 | 0.46% |
| Shared Office Services Pty Ltd | 15,839,358 | 0.37% |